AzTrials
AzTrials

PainNCT00200590

Analgesic Strategies in Newborns Receiving Prostaglandin Therapy

A study testing acetaminophen and nalbuphine, acetaminophen and morphine and acetaminophen and reduced dosage of prostaglandin in people with Pain, run by Nantes University Hospital at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is a randomised trial comparing the efficacy of 3 different analgesic strategies in newborns on prostaglandin for ductus dependent congenital heart disease. Read more about this study

Who is it for?
Ages Up to 28 days
Conditions the study is for
Pain
What is being tested?
acetaminophen and nalbuphine, acetaminophen and morphine and acetaminophen and reduced dosage of prostaglandin
How many people
30 participants
Where
1 siteFrance
Study dates
Dec 2003to Jul 2006
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 28 days
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Full-term newborn
  • Under one month of age
  • With ductus dependent congenital heart disease requiring prostaglandin infusion and elevated pain score

Who cannot join

  • Contraindication to either morphine, acetaminophen, or nalbuphine
  • Other painful condition
  • Poor neurological condition
  • Cardiac instability requiring urgent surgery

Trial locations and contacts

1 site in 1 country.

France1 site
  • Nantes University Hospital

    Nantes, 44093

Other trials in France

About this study

This is a randomised trial comparing the efficacy of 3 different analgesic strategies in newborns on prostaglandin for ductus dependent congenital heart disease.

Conditions
Pain
Being tested
acetaminophen and nalbuphine, acetaminophen and morphine, acetaminophen and reduced dosage of prostaglandin
Keywords
prostaglandin, analgesia, congenital, heart, defect, induced
Medical subject headings
Pain, Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • acetaminophen and nalbuphineDrug

  • acetaminophen and morphineDrug

  • acetaminophen and reduced dosage of prostaglandinDrug

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain score

    Measured: before inclusion and at 8 hours (H8), H24, H48, H72

Secondary outcomes (4)
  1. Incidence of apnea

  2. Need for mechanical ventilation

  3. Incidence of fever

  4. Pattern of feeding (oral, nasogastric [NG] tubing, parenteral nutrition)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Sep 2005 (estimated)
  2. Study startDec 2003
  3. Primary completionJul 2006
  4. Study completionJul 2006

Why it stopped: More important number of SAE in one arms

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00200590
Sponsor's protocol ID
BRD/03/7-D
Status last verified
Apr 2008
First submitted
12 Sep 2005
Last updated
21 Apr 2008
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing acetaminophen and nalbuphine, acetaminophen and morphine and acetaminophen and reduced dosage of prostaglandin in people with Pain, run by Nantes University Hospital at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 21 Apr 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: More important number of SAE in one arms). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain score (time frame: before inclusion and at 8 hours (H8), H24, H48, H72). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in